Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Regorafenib/sintilimab/sorafenib

Multiple toxicities: 5 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Huang J, et al. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma 9: 157-170, 2022. Available from: URL: http://doi.org/10.2147/JHC.S353956 Huang J, et al. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma 9: 157-170, 2022. Available from: URL: http://​doi.​org/​10.​2147/​JHC.​S353956
Metadaten
Titel
Regorafenib/sintilimab/sorafenib
Multiple toxicities: 5 case reports
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-14827-9

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Streptozocin

Case report

Isoprenaline

Case report

Prednisone

Case report

Multiple drugs